http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018043934-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d9072cb25d6ae674a3943f14e5771e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_488317cdcb9b5c462fec4be2eaf9d4eb |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14 |
| filingDate | 2016-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fe8c024aaad0791a578a11b7f770daa |
| publicationDate | 2018-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018043934-A |
| titleOfInvention | Prophylactic or therapeutic agent for neurological diseases that develop with abnormal aggregation of neurodegenerative disease protein, and screening method for the prophylactic or therapeutic agent |
| abstract | A prophylactic or therapeutic agent for a neurological disease (for example, Alzheimer type dementia, FTLD, HD, etc.) that develops with abnormal aggregation of a neurodegenerative disease protein, and a method for screening the prophylactic or therapeutic agent. . A preventive or therapeutic agent for a neurological disease that develops with abnormal aggregation of a neurodegenerative disease protein, comprising hepta-histidine, angiotensin III, luteinizing hormone-releasing hormone peptide fragment, hepta-glutamine, kemptide acetate, A compound having an amino acid sequence of 80% or more identity with those compounds and having affinity for a protein that directly interacts with the neurodegenerative disease protein, and nordihydroguaiaretic acid ester, sphingosine-1-phosphate, And a prophylactic or therapeutic agent comprising, as an active ingredient, at least one compound selected from the group consisting of those compounds and chemically modified compounds thereof. [Selection] Figure 1 |
| priorityDate | 2016-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 172.